TherapeuticsMD, Inc.: Form 10-K for the period ended Dec 31, 2019
Filed with the SEC on Feb 24, 2020 and accepted by EDGAR at Feb 24, 2020, 16:18 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-10-01 to 2019-12-31 | $15.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2019-01-01 to 2019-12-31 | $49.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2019-01-01 to 2019-12-31 | $6.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2019-10-01 to 2019-12-31 | $13.0m | us-gaap:GrossProfit |
| Gross profit | 12 months2019-01-01 to 2019-12-31 | $43.3m | us-gaap:GrossProfit |
| Research and development | 12 months2019-01-01 to 2019-12-31 | $19.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2019-01-01 to 2019-12-31 | $174.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2019-01-01 to 2019-12-31 | −$151.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2019-01-01 to 2019-12-31 | $17.4m | us-gaap:InterestExpense |
| Net income | 3 months2019-10-01 to 2019-12-31 | −$49.4m | us-gaap:NetIncomeLoss |
| Net income | 12 months2019-01-01 to 2019-12-31 | −$176.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-10-01 to 2019-12-31 | −$0.19 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months2019-01-01 to 2019-12-31 | −$0.72 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | −$165.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | $2.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-12-31 | $160.8m | us-gaap:Cash |
| Current assets | At period end2019-12-31 | $208.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $266.0m | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $53.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-12-31 | $256.8m | us-gaap:Liabilities |
| Long-term debt | At period end2019-12-31 | $194.6m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2019-12-31 | $9.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001387131-20-002086. Last ingested by Listed: Nov 14, 2026, 19:24 ET. Listed shows no prices and gives no investment advice.